NCT07343245 A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs
| NCT ID | NCT07343245 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Daewon Pharmaceutical Co., Ltd. |
| Condition | Healthy Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-02-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 150 participants in total. It began in 2025-12-01 with a primary completion date of 2026-02-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Drug-Drug Interaction between DW4421 and three different kinds of NSAIDs
Eligibility Criteria
Inclusion Criteria: * Healthy adult aged 19 to 50 (inclusive) years, at the time of screening. * Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg/m2 (inclusive) at screening visit. Exclusion Criteria: * Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history
Frequently Asked Questions
Who can join the NCT07343245 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 50 Years, studying Healthy Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07343245 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07343245 currently recruiting?
Yes, NCT07343245 is actively recruiting participants. Visit ClinicalTrials.gov or contact Daewon Pharmaceutical Co., Ltd. to inquire about joining.
Where is the NCT07343245 trial being conducted?
This trial is being conducted at Cheongju-si, South Korea.
Who is sponsoring the NCT07343245 clinical trial?
NCT07343245 is sponsored by Daewon Pharmaceutical Co., Ltd.. The trial plans to enroll 150 participants.